Egis Gyogyszergyar Rt.

Egis Pharmaceutical

Gis Gyogyszergyar Rt.

Egis Gyoyszergyar Rt

Andras Egyed

Gabor Blasko

Gyula Simig

Istvan Gyertyan

Istvan Gacsalyi

Katalin Szemeredi

Zoltan Budai

Tibor Mezei

Marton Fekete

Gabor Gigler

Eva Schmidt

Andras Bilkei-Gorzo

Karoly Tihanyi

Judit Bajnogel

Daniel Bozsing

Klara Reiter Nee Esses

Klara Kazo Nee Daroczi

Csaba Szantay

Gabor Kovacs

Imre Moravcsik

Ferenc Andrasi

Jozsef Barkoczy

Tamas Hamori

Eniko Szirt Nee Kiszelly

Pal Berzsenyi

Gabor Nemeth

Jozsef Reiter

Imre Klebovich

Gabor Zolyomi

Gyula Lukacs

Pal Vago

Lajos Novak

Katalin Pallagi

Margit Csorgo

Eszter Szentkuti

Sandor Drabant

Anna Bakonyi

Katalin Horvath

Imre Doman

Enik Szirt Nee Kiszelly

Peter Kovacs

Gyorgyne Mate

Edit Horvath

Klara Gado

Geza Szabo

Aniko Miklos Nee Kovacs

Zoltan Ratkai

Julianna Takacs Nee Bitai

Gyorgy Pirok

Cecilia Salamon Haskane

Peter Korosi

Hilda Botka

Klara Daroczi Kazone

Gyula Balogh, Deceased

Erzsebet Kovacs Nee Kaszab

Eniko Szirt Nee Kislelly

Kalara Reiter Nee Esses

Erika Karaffa

Gyula Grezal

Katalin Baloghne Nemes

Miklos Abermann

Andras Bilkei Gorzo

Erzsebet Kaufmanne Bojti

Ildiko Ratz Nee Simonek

Ivan Jakoczi

Bernadett Martonné Marko

György Levay

Annamaria Simo

The invention relates to new 2,3-benzodiazepine derivatives of general Formula (I), (wherein Rstands for methyl, formyl, carboxy, cyano, &#x2014;CH&#x2550;NOH, &#x2014;CH&#x2550;NNHCONHor &#x2014;NRR, wherein Rand Rindependently from each other represent hydrogen or lower alkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris nitro or amino; Rstands for hydrogen, lower alkanoyl or CO&#x2014;NRR, wherein Rand Rindependently from each other stand for hydrogen, lower alkoxy, lower alkyl or lower cycloalkyl or together with the nitrogen atom, they are attached to, form a 5- or 6-membered, saturated or unsaturated heterocyclic ring optionally containing one or more further nitrogen, sulfur and/or oxygen atom(s); Ris hydrogen or lower alkyl; the dotted lines have the following meaning: if Rand Rare not present, the bond between positions Cand Cis a single bond and the bond between positions Cand Nis a double bond; if Rand Rare present, the bonds between positions Cand Cand between position Cand Nare single bonds; and if Ris present and Ris missing, the bond between positions Cand Cis a double bond and the bond between positions Cand Nis a single bond) and salts thereof. The invention compounds have neuroprotective effect.

2,3-benzodiazepine derivatives

Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions

1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives as anxiolytic agents

This invention relates to new 1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of the said benzodiazepine derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The compounds according to the invention correspond to the general formula (I), ##STR1## wherein the variables are herein below defined, and the compounds possess central nervous activities.

1-�2-(substituted vinyl)!-5H-2,3-benzodiazepine derivatives

The invention relates to anxiolytic pharmaceutical compositions comprising as active ingredient 1-sytrylisoquinoline derivatives of general formula (I), wherein

Heterocyclic compounds, pharmaceutical compositions comprising them and

This invention relates to new oxaindene derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The compounds according to the invention are characterized by the general formula (1) ##STR1## wherein R.sup.1 represents lower C.sub.1-4 alkyl, lower C.sub.1-4 alkoxy or lower C.sub.3-6 cycloalkyl,

Oxaindene derivatives and process for the preparation thereof

The invention refers to pharmaceutical compositions for the prevention and/or treatment of gastrointestinal diseases connected with infections caused by Helicobacter pylori and a method for the treatment of such diseases. The pharmaceutical composition of the invention comprises as active ingredient a cyclic ketone derivative of the formula I ##STR1## wherein and R.sup.1 mean independently hydrogen or halo;

Pharmaceutical compositions for the prevention and/or treatment a

The invention relates to novel, pharmaceutically active trisubstituted cycloalkane derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The invention also encompasses the use of the said cycloalkane derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases. The compounds according to the invention are characterized by the general formula (I), ##STR1## wherein R represents hydrogen, C.sub.1-4 alkyl or hydroxyl,

Trisubstituted cycloalkane derivatives and process for the preparation

Novel basic ether of general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen or C.sub.1-4 alkoxy, or together they represent a 3,4-methylenedioxy group,

Basic ethers and process for the preparation thereof

Growing community of inventors

Budapest, Hungary

Andras Egyed